Ping Luo1, Shugui Wu2, Kaibao Ji3, Xia Yuan4, Hongmi Li4, Jinping Chen5, Yunfei Tian6, Yang Qiu4, Xiaoming Zhong4. 1. Department of Breast Tumor of Nanchang Third Hospital, Nanchang, Jiangxi, China. 2. Department of Oncology of Ganzhou People's Hospital, Ganzhou, Jiangxi, China. 3. Department of Ophthalmology, Renmin Hospital of Wuhan University, Hubei, China. 4. Department of Tumor Radiotherapy of Jiangxi Province Cancer Hospital, Nanchang, Jiangxi, China. 5. Department of Oncology of Yichun People's Hospital, Yichun, Jiangxi, China. 6. Department of Interventional of Ganzhou People's Hospital, Ganzhou, Jiangxi, China.
Abstract
PURPOSE: Cisplatin resistance is still a serious problem in the clinic. However, the underlying mechanism remains unknown. In our study, we investigated cisplatin resistance by using the cisplatin-resistant cell line HCT116R. METHODS: The HCT116 cell line, a colon cancer cell line, was purchased. Cell viability was determined using CCK-8 Assay Kit. The gene expression levels of MIR4435-2HG, Nrf2, and HO-1, and caspase activity were determined using qRT-PCR and Caspase 3 Assay Kit, respectively. RESULTS: In this study, we found that the levels of the lncRNA MIR4435-2HG were dramatically increased in the cisplatin-resistant cell line HCT116R. Knockdown of MIR4435-2HG in HCT116R cells significantly restored the sensitivity to cisplatin, inhibited cell proliferation and promoted cell apoptosis. Furthermore, Nrf2 and HO-1 mRNA levels, as critical molecules in the oxidative stress pathway, were inhibited by siRNAs targeting MIR4435-2HG, suggesting that MIR4435-2HG-mediated cisplatin resistance occurs through the Nrf2/HO-1 pathway. CONCLUSION: Our findings demonstrate that the lncRNA MIR4435-2HG is a main factor driving the cisplatin resistance of HCT116 cells.
PURPOSE:Cisplatin resistance is still a serious problem in the clinic. However, the underlying mechanism remains unknown. In our study, we investigated cisplatin resistance by using the cisplatin-resistant cell line HCT116R. METHODS: The HCT116 cell line, a colon cancer cell line, was purchased. Cell viability was determined using CCK-8 Assay Kit. The gene expression levels of MIR4435-2HG, Nrf2, and HO-1, and caspase activity were determined using qRT-PCR and Caspase 3 Assay Kit, respectively. RESULTS: In this study, we found that the levels of the lncRNA MIR4435-2HG were dramatically increased in the cisplatin-resistant cell line HCT116R. Knockdown of MIR4435-2HG in HCT116R cells significantly restored the sensitivity to cisplatin, inhibited cell proliferation and promoted cell apoptosis. Furthermore, Nrf2 and HO-1 mRNA levels, as critical molecules in the oxidative stress pathway, were inhibited by siRNAs targeting MIR4435-2HG, suggesting that MIR4435-2HG-mediated cisplatin resistance occurs through the Nrf2/HO-1 pathway. CONCLUSION: Our findings demonstrate that the lncRNA MIR4435-2HG is a main factor driving the cisplatin resistance of HCT116 cells.
Colon cancer is one of the most common malignant tumors in the world. At present, there are more than 1 million new cases of colon cancer each year, which seriously endangers human life and the quality of life [1]. Most patients with metastatic colorectal cancer cannot be cured. The positive response ratio to combined chemotherapy for colon cancer is only 20–47%, and most patients have recurrence [2]. Cisplatin is widely used to treat a variety of cancers [3]. However, drug resistance frequently occurs after a period of administration and an effective response, and its specific mechanism is still not very clear [4]. It has been shown that long noncoding RNA (lncRNA) interacts with chromatin regulatory proteins, RNA-binding proteins, and small RNAs to form a functional complex, regulating multiple important biological processes [5-7]. To investigate the role of the lncRNA MIR4435-2HG in cisplatin resistance, we disrupted the expression of MIR4435-2HG in cisplatin-resistant HCT116R cells, and these cells became sensitive to cisplatin. At the same time, Nrf2 and HO-1 mRNA levels also decreased.
Materials and methods
Cell culture and reagents
The colon cancer cell line HCT116 was purchased from the American Type Culture Collection (Manassas, VA, USA). This is a cisplatin-sensitive cell line, and a cisplatin-resistant cell line, HCT116R, was established from the parental HCT116 cells by selection with cisplatin in the laboratory. HCT116 cells were seeded at a density of 2.5x105 cells /well and subjected to treatment with 25 μM cisplatin for three months. The culture medium containing 25 μM cisplatin was renewed twice a week. Both HCT116 and HCT116R cells were maintained as a monolayer in McCoy’s 5A medium (Gibco, Life Technologies, USA) supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 μg/ml) in a humidified atmosphere of 5% CO2 at 37°C. Scramble and MIR4435-2HG siRNAs were purchased from Thermo Fisher (China), and siRNA transfections were performed with Lipofectamine 2000 (Life Technologies).
Cell proliferation assays
The cell proliferation procedure was performed as previously described [8]. Briefly, cell proliferation was determined with WST-8 assay using Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan). HCT116 cells (5×103/well) were seeded in 96-well plates and incubated for 24 h. Cells were incubated with or without 25 μM cisplatin for 24 h in McCoy’s 5A medium. Each treatment was carried out in triplicates. After adding 10 μL CCK-8 reagent to each well, the plates were incubated at 37°C and 5% CO2 for another 4 h. Then, absorbance was determined at 450 nm using Microplate Reader (Multiskan JX; MTX Lab Systems, Vienna, VA, USA).
Total RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR)
The procedure for this section has been described previously [9]. Total RNA was isolated from treated cells using Trizol Reagent (Invitrogen, Carlsbad, CA) following manufacturer’s guidelines. RNA concentration and quality were determined by spectrophotometer (Beckman, Brea, CA) and gel electrophoresis, respectively. First-strand cDNA was synthesized using the M-MLV Reverse Transcriptase kit (Invitrogen, Carlsbad, CA) in a total volume of 20 ul. qRT-PCR analysis for gene expression was performed in triplicate using SYBR Green.
Caspase-3 activity assay
Cells were seeded into 96-well plates at a density of 5,000 cells/ well and allowed to grow for 24h. Then, siRNAs targeting MIR4435-2HG were transfected by Lipofectamine RNAiMAX (ThermoFisher, China) according to the instruction manual. Cells were harvested after 24 h, and caspase activity was examined by the Caspase-3 Assay Kit (Colorimetric) (Abcam ab39401, Cambridge, UK).
Statistical analysis
Data were presented as the mean± standard error of the mean. Statistical analysis was performed using Prism GraphPad 6.0 (GraphPad Software, San Diego, CA, USA). p <0.05 was considered significant.
Results
The MIR4435 level is increased in HCT116 cells resistant to cisplatin
First, we induced the drug resistance of HCT116 to cisplatin by adding 25 μM cisplatin to HCT116 cells for 3 months, and we named the resulting line HCT116R. HCT116R cells proliferated in the presence of 25 μM cisplatin, while most HCT116 cells progressively died (Fig 1A). We detected the response to cisplatin. Then, We found that the level of the lncRNA MIR4435-2HG dramatically increased by approximately ten times, and this result was verified with real-time PCR (Fig 1B).
Fig 1
The MIR4435 level was increased in the HCT116 cell line resistant to cisplatin.
A. HCT116 and HCT116R cells were treated with 25 μM cisplatin, and the cell viability was tested by the WST assay 0, 8 and 24 h later. B. MIR4435-2HG levels in HCT116 and HCT116R cells were detected by real-time PCR. ** P < 0.01, *** P < 0.001, **** P < 0.0001.
The MIR4435 level was increased in the HCT116 cell line resistant to cisplatin.
A. HCT116 and HCT116R cells were treated with 25 μM cisplatin, and the cell viability was tested by the WST assay 0, 8 and 24 h later. B. MIR4435-2HG levels in HCT116 and HCT116R cells were detected by real-time PCR. ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Knockdown of MIR4435-2HG improved the sensitivity of HCT116R cells to cisplatin
To investigate the relationship between the lncRNA MIR4435-2HG and cisplatin resistance, we knocked down MIR4435-2HG by siRNA in HCT116R cells, and the MIR4435-2HG level dramatically decreased after siRNA transfection, which was verified by real-time PCR (Fig 2A). The knockdown of MIR4435-HG2 by siRNA increased the sensitivity of HCT116R cells to cisplatin, and the cell viability was tested by WST assay. In the presence of 25 μM cisplatin, HCT116R cell proliferation was inhibited by the siRNA targeting MIR4435-2HG, while there was no significant effect with the scrambled siRNA sequence (Fig 2B). After knockdown of MIR4435-2HG, cisplatin administration increased caspase-3 activity approximately 2-fold (Fig 2C), which indicated that HCT116R cell apoptosis occurred.
Fig 2
Transient knockdown of MIR4435 by siRNA sensitized HCT116R cells to cisplatin.
A. MIR4435-2HG was knocked down in HCT116R cells by siRNA, and the effect of siRNA was verified by real-time PCR. B. Knockdown of MIR4435-HG2 by siRNA increased the sensitivity of HCT116R cells to cisplatin, and the cell viability was tested by the WST assay 0, 8 and 24 h after the administration of cisplatin. C The caspase-3 activity was tested 24 h after the cisplatin treatment. The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, **** P < 0.0001.
Transient knockdown of MIR4435 by siRNA sensitized HCT116R cells to cisplatin.
A. MIR4435-2HG was knocked down in HCT116R cells by siRNA, and the effect of siRNA was verified by real-time PCR. B. Knockdown of MIR4435-HG2 by siRNA increased the sensitivity of HCT116R cells to cisplatin, and the cell viability was tested by the WST assay 0, 8 and 24 h after the administration of cisplatin. C The caspase-3 activity was tested 24 h after the cisplatin treatment. The data are presented as the means ± SDs. * P < 0.05, ** P < 0.01, **** P < 0.0001.
Knockdown of MIR4435-2HG decreased Nrf2 and HO-1 mRNA levels related to oxidative damage
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcription factor that regulates antioxidant and detoxification enzymes, and heme oxygenase-1 (HO-1) is an Nrf2-regulated gene which performs a crucial role in the precaution of inflammation. Transfection with MIR4435-2HG siRNA downregulated the mRNA levels of Nrf2 and HO1 significantly after treatment with 25 μM cisplatin (Fig 3), and this phenomenon indicates that MIR4435-2HG is involved in oxidative stress.
Fig 3
Knockdown of MIR4435 decreased the NRF2 and HO-1 mRNA levels related to oxidative damage.
The relative NRF2 (A) and HO-1 mRNA (B) levels of HCT116R cells were analyzed by real-time PCR, and the results were normalized to the reference gene, GAPDH. The data are presented as the means ± SDs. * P < 0.05.
Knockdown of MIR4435 decreased the NRF2 and HO-1 mRNA levels related to oxidative damage.
The relative NRF2 (A) and HO-1 mRNA (B) levels of HCT116R cells were analyzed by real-time PCR, and the results were normalized to the reference gene, GAPDH. The data are presented as the means ± SDs. * P < 0.05.
Discussion
Cisplatin is thought to generate covalent adducts between some bases in DNA and can cure certain kinds of testicular and ovarian carcinomas [10, 11]. However, the efficiency of cisplatin is low in treatment of colorectal cancer (CRC), and less than 20% of patients achieved clinical response using it alone or in combination with other drugs [12]. Over the last few years, several studies have suggested that some lncRNAs contribute to cisplatin resistance via various mechanisms[13].The lncRNA MIR4435-2HG has been reported to be related to hepatocellular carcinoma [14] and lung cancer [15]. Wen et al. found that MIR4435-2HG might participate in the development of colorectal cancer via the P38/MAPK and VEGF pathways[16]. In this report, we found that the level of MIR4435-2HG was increased approximately 7-8-fold in cisplatin-resistant cell lines compared to its expression in normal cell lines, which implies that MIR4435-2HG may be involved in cisplatin resistance. Then, we knocked down MIR4435-2HG with siRNA, and approximately 90% of MIR4435-2HG expression was inhibited by siRNA in cisplatin-resistant HCT116R cells. The effect of MIR4435-2HG knockdown in HCT116R cells was that 24 h of cisplatin administration caused approximately one-third of HCT116R cells to die. As a control, HCT116R cells without disruption of MIR4435-2HG expression proliferated approximately twice as much in 24 h. The cisplatin-resistant HCT116R cells became sensitive to cisplatin after MIR4435-2HG knockdown. In addition, after 24 h of cisplatin treatment, the caspase-3 activity increased 2.5-fold in the MIR4435-2HG knockdown cells compared to that in HCT116R cells, while the scramble siRNA did not have any effect. These results indicate that cisplatin-induced cell death may mainly occur via apoptosis.Nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor, responds to oxidative stresses and plays a key role in redox homeostasis [17]. Heme oxygenase (HO), acting downstream of Nrf2 [18], is an enzyme that catalyzes the degradation of heme [19, 20]. These two components are usually increased in different types of tumors and correlate with tumor progression, aggressiveness, resistance to therapy, and poor prognosis [21]. In our system, the knockdown of MIR4435-2HG significantly decreased NRF2 and HO-1 mRNA levels.
Conclusions and perspectives
In this report, we observed that the lncRNA MIR4435-2HG was a main factor driving cisplatin resistance in HCT116 cells. Moreover, MIR4435-2HG might contribute to the development of cisplatin resistance through the Nrf2/HO-1 pathway. The current study discovered the roles of MIR4435-2HG in colorectal cancercisplatin resistance and provided the underlying mechanism of cisplatin resistance.By increasing our understanding of the underlying mechanisms of cisplatin resistance, we can develop better colorectal treatments with lower treatment resistance by adopting the following strategies. Firstly, new platinum-based drug research and development should be expedited. Secondly, studies should find methods to increase the efficiency of cisplatin delivery to tumors. Thirdly, experimental research should be carried out to target cisplatin resistance mechanisms. Lastly, integrating cisplatin with other drugs should be considered. A greater understanding of cisplatin resistance mechanism can help identify which patients respond to therapy. Therefore, oncologists can make the best-informed decision when choosing effective therapy for patients.12 Dec 2019PONE-D-19-25514LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1PLOS ONEDear Mr. Zhong,Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.Please consider the comments of Reviewer #1 before submitting a revised manuscript.We would appreciate receiving your revised manuscript by Jan 26 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocolsPlease include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.We look forward to receiving your revised manuscript.Kind regards,Salvatore V PizzoAcademic EditorPLOS ONEJournal Requirements:When submitting your revision, we need you to address these additional requirements.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found athttp://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf1. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:https://doi.org/10.1111/jgh.13069https://doi.org/10.1097/PGP.0000000000000079https://doi.org/10.7717/peerj.6683https://doi.org/10.2147/DDDT.S106412In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.2. Please note that all PLOS journals ask authors to adhere to our policies for sharing of data and materials: https://journals.plos.org/plosone/s/data-availability. According to PLOS ONE’s Data Availability policy, we require that the minimal dataset underlying results reported in the submission must be made immediately and freely available at the time of publication. As such, please remove any instances of 'unpublished data' or 'data not shown' in your manuscript and replace these with either the relevant data (in the form of additional figures, tables or descriptive text, as appropriate), a citation to where the data can be found, or remove altogether any statements supported by data not presented in the manuscript. Particularly, either include as a Supporting file the RNA-seq data you mention at the beginning of your Results section and add the corresponding methodology in the Methods section, or consider removing the sentence altogether.3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ[Note: HTML markup is below. Please do not edit.]Reviewers' comments:Reviewer's Responses to QuestionsComments to the Author1. Is the manuscript technically sound, and do the data support the conclusions?The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.Reviewer #1: Yes**********2. Has the statistical analysis been performed appropriately and rigorously?Reviewer #1: Yes**********3. Have the authors made all data underlying the findings in their manuscript fully available?The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.Reviewer #1: Yes**********4. Is the manuscript presented in an intelligible fashion and written in standard English?PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.Reviewer #1: Yes**********5. Review Comments to the AuthorPlease use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)Reviewer #1: The Cohen's d factors are large enough so the results are clear and unambiguous. The results may provide the useful tool how to circumvent the resistance to cisplatin beside the determination of polimorfisms of proteins involved in transport of cisplatin.**********6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.If you choose “no”, your identity will remain anonymous but your review may still be made public.Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.Reviewer #1: Yes: Tomaž Makovec[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.Submitted filename: Minor revisions.docxClick here for additional data file.3 Jul 2020Dear Tomaž Makovec and Salvatore V Pizzo,Thanks for your comments. We really appreciate your hard work. We really hope our manuscript can be published in your journal. Thank you for your consideration. And if you have any more queries, please notify us in a timely manner.Best wishes,Mr. ZhongSubmitted filename: Response to Reviewers.docxClick here for additional data file.18 Aug 2020LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1PONE-D-19-25514R1Dear Dr. Zhong,We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.Kind regards,Salvatore V PizzoAcademic EditorPLOS ONEAdditional Editor Comments (optional):Reviewers' comments:12 Nov 2020PONE-D-19-25514R1LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1Dear Dr. Zhong:I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.If we can help with anything else, please email us at plosone@plos.org.Thank you for submitting your work to PLOS ONE and supporting open access.Kind regards,PLOS ONE Editorial Office Staffon behalf ofDr. Salvatore V PizzoAcademic EditorPLOS ONE
Authors: Al B Benson; Alan P Venook; Lynette Cederquist; Emily Chan; Yi-Jen Chen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Peter C Enzinger; Alessandro Fichera; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Christina S Wu; Kristina M Gregory; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2017-03 Impact factor: 11.908
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: A L Furfaro; N Traverso; C Domenicotti; S Piras; L Moretta; U M Marinari; M A Pronzato; M Nitti Journal: Oxid Med Cell Longev Date: 2015-11-30 Impact factor: 6.543
Authors: L Galluzzi; I Vitale; J Michels; C Brenner; G Szabadkai; A Harel-Bellan; M Castedo; G Kroemer Journal: Cell Death Dis Date: 2014-05-29 Impact factor: 8.469
Fig 1
Fig 2
Fig 3